Faculty

Back to Index
Syma Iqbal, MD
Associate Professor of Clinical Medicine
Medicine
NOR 3457 Health Sciences Campus Los Angeles
+1 323 865 3907

Overview

Born in London and raised in California, Dr. Iqbal graduated from the Keck School of Medicine of USC in 1995 and completed a Hematology and Oncology Fellowship in 2001. She is currently an Associate Professor in the Division of Oncology and Assistant Program Director the Oncology Department’s Fellowship Program. Additional clinical administrative appointments include the Division of Oncology’s Educational Officer and Co-Director of the Liver Cancer Program at USC.

Dr. Iqbal also serves as an assistant editor for Women’s Oncology Review and sits on the Clinical Investigations Committee and the Pharmacy Review Committee at the Keck School of Medicine. She has several research activities in progress and has received grants for fifteen studies. In addition to her numerous authored articles, book chapters and abstracts, that have published in medical journals and texts, she has been an invited lecturer at conferences across California, as well as cities including Chicago, Denver, Kansas City, Dallas and Maui.

Publications

. View in: PubMed

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr; 18(4):446-453. View in: PubMed

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Feb 17. View in: PubMed

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015 Jul 1; 121(13):2193-7. View in: PubMed

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015 Jul 01; 121(13):2193-7. View in: PubMed

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. View in: PubMed

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014 Oct 1; 120(19):2980-5. View in: PubMed

Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014 Oct 01; 120(19):2980-5. View in: PubMed

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32(1):113-22. View in: PubMed

New directions in perioperative management of locally advanced esophagogastric cancer. Am Soc Clin Oncol Educ Book. 2014; e172-8. View in: PubMed

New directions in perioperative management of locally advanced esophagogastric cancer. Am Soc Clin Oncol Educ Book. 2014; 34:e172-8. View in: PubMed

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. View in: PubMed

Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. Ann Surg Oncol. 2012 Feb; 19(2):478-85. View in: PubMed

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. View in: PubMed

S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29(34):4555-60. View in: PubMed

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 01; 29(34):4555-60. View in: PubMed

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. View in: PubMed

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics. 2011 Jan; 12(1):27-39. View in: PubMed

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010 Sep; 5(9):1472-6. View in: PubMed

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. View in: PubMed

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. View in: PubMed

Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008 Apr 15; 68(8):3037-42. View in: PubMed

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. View in: PubMed

Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007 Dec; 8(12):1705-13. View in: PubMed

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007 Aug 20; 25(24):3726-31. View in: PubMed

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20; 25(24):3712-8. View in: PubMed

ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2007 Jan; 1(1):23-30. View in: PubMed

Molecular determinants of irinotecan efficacy. Int J Cancer. 2006 Nov 15; 119(10):2435-42. View in: PubMed

Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. View in: PubMed

Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. View in: PubMed

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. View in: PubMed

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics. 2006 Jul; 16(7):475-83. View in: PubMed

Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics. 2006 Jan; 7(1):67-88. View in: PubMed

Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. View in: PubMed

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005 Oct; 23(5):485-7. View in: PubMed

Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule. Cancer Chemother Pharmacol. 2005 Jul; 56(1):75-82. View in: PubMed

Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005 May 20; 23(15):3536-44. View in: PubMed

Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 17):10-6. View in: PubMed

Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Expert Rev Anticancer Ther. 2004 Dec; 4(6):947-55. View in: PubMed

Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S32-9. View in: PubMed

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics. 2004 May; 14(5):319-27. View in: PubMed

Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest. 2004; 22(5):762-73. View in: PubMed

Molecular predictors of treatment and outcome in colorectal cancer. Curr Gastroenterol Rep. 2003 Oct; 5(5):399-405. View in: PubMed

Targeted therapy and pharmacogenomic programs. Cancer. 2003 Apr 15; 97(8 Suppl):2076-82. View in: PubMed

Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002 Sep; 118(4):1166-9. View in: PubMed

Powered bySC CTSI